Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
about
CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitisThe potential utility of B cell-directed biologic therapy in autoimmune diseases.Diabetes insipidus as a complication of Wegener's granulomatosis and its treatment with biologic agents.Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case seriesAdvances in the use of biologic agents for the treatment of systemic vasculitisRituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitisRheumatoid vasculitis: vanishing menace or target for new treatments?Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab.Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabRituximab for the treatment of Churg-Strauss syndrome with renal involvement.Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamideUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Clinical use of biologics in vasculitis syndromes.Primary systemic vasculitis: treatment of difficult cases.Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?The emerging role of rituximab in organ transplantation.Current pharmacotherapy for the treatment of crescentic glomerulonephritis.Off-label uses of rituximab in dermatology.Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trialMolecularly targeted therapies for dysimmune neuropathiesHematopoietic stem cell transplantation (HSCT) for primary systemic vasculitis and related diseases.Pharmacotherapy of vasculitis.Effectiveness of rituximab in severe Wegener's granulomatosis: report of two cases and review of the literature.Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitisRecommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?The role of biologics in treatment of ANCA-associated vasculitis.B-cell-targeted therapy in adult glomerulonephritis.Biologic therapy for refractory scleritis: a new treatment perspective.Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report.Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis.Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome.Biologic therapy in primary systemic vasculitis of the young.Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes.Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden.Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease.Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis.
P2860
Q27486517-BB0BBD43-B226-4BD4-A7F1-889C39C80F6AQ33377109-65B945AB-8B15-40CA-99E6-DBE09100B289Q33602540-AC818A68-4AF2-482A-A2C8-F47A859F8D5AQ33757209-9D48486D-00C5-4F60-98C5-03C7AE76320DQ34065598-5DB52EA7-9F0F-4585-8342-8BBCB6D3A961Q34075484-386084B3-5285-45E0-8EF0-1A725721DF66Q34176634-7C64ADD2-E294-49C7-BF24-6ED3E0B3A940Q34244998-83AF82E7-9D33-4DF8-9E4B-B8897E9125ABQ35065425-53BD39EF-AD3F-4BBB-ACDB-C5B7B6615E69Q35557092-200C1CC6-C355-46D7-BD27-DBBC65055363Q35662018-087AA4B9-DBF5-4654-9671-685A34B7EA9AQ35887318-8F18E560-58C3-4BE1-9733-5C8A806C5C07Q35953330-DF105C48-B074-4B0C-9648-A23FD838FAB4Q36171750-E46FF4DE-EC59-49D4-90B6-A659C820500BQ36358081-4138D812-CE0D-46A8-851E-D544BF158718Q36458145-9B492901-D3FE-44B4-9989-B9F938FE0B16Q36504479-954965D0-51D6-4352-AEE5-E7585AFE28BAQ36530278-25946BC4-894E-42B0-8CF9-56C327AFAB1EQ36623061-E68272B0-69D3-4D21-A7BE-44E67E2D2687Q36986050-4554C588-E177-4FE6-B09D-11B6135153D1Q37144563-D8BCF71D-60B1-4219-8261-E3768A092BDEQ37254545-D5D62563-1F98-4E8D-93C7-9EDD003B7B65Q37311093-5DE41DFA-0D24-4EC0-B8A1-02CC673046EAQ37483910-2FBFEEC5-FEB3-4759-B923-BF8B15CB5A87Q37546823-503D9120-5DBB-489A-9DD2-5CB979E81182Q37640836-D2B78161-579E-4574-A479-D6AE6059B366Q37879814-3606BA60-30A9-4391-8784-EC2715CBFEF4Q37912214-8E2934D7-7B71-41BA-A033-6606D73A212DQ37950904-51A4618F-08A7-43B7-A3C5-CB2FF6A4E470Q38159787-64E3CE11-41D4-4F94-AED3-3B01DF2A4990Q38576234-8058F5CB-AD22-424A-A09D-78E4C9B543DDQ39314270-79584685-01D4-4A1C-97CE-37C5B9674270Q42539284-B67C4A26-59F5-4E06-B2A8-B7C461F16D0BQ42955730-C55C772F-0F87-4B2C-A997-31821BBD224AQ45964920-478EFBF9-F442-4A9F-BA10-6E40A8BD3F68Q47581564-44D74455-646F-4B1E-9B78-872BA5A45F2AQ49691317-1ADF4BF5-F3BB-430E-8E96-60A26D71EEFAQ50598390-5532CB4B-268F-4A6D-986D-CA4D741F138EQ50850119-593D4286-72E3-49EB-BA49-1AEA2887FF8BQ52915030-1DAA72FE-A443-4A22-AC78-DD5DC61FAC7D
P2860
Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Nine patients with anti-neutro ...... sfully treated with rituximab.
@en
Nine patients with anti-neutro ...... sfully treated with rituximab.
@nl
type
label
Nine patients with anti-neutro ...... sfully treated with rituximab.
@en
Nine patients with anti-neutro ...... sfully treated with rituximab.
@nl
prefLabel
Nine patients with anti-neutro ...... sfully treated with rituximab.
@en
Nine patients with anti-neutro ...... sfully treated with rituximab.
@nl
P2860
P1476
Nine patients with anti-neutro ...... sfully treated with rituximab.
@en
P2093
Eriksson P
P2860
P304
P356
10.1111/J.1365-2796.2005.01494.X
P407
P577
2005-06-01T00:00:00Z